The U.S. will likely emerge the winner in a "cold currency war" that is heating up, an expert said.Currenciesread more
These box office numbers do not include the cost of production or marketing costs. They also don't count the billions in merchandising that Disney has made over the last...Entertainmentread more
Tariffs are the only instrument left for addressing China's systematic and excessive surpluses on its U.S. trades, writes Michael Ivanovitch.US Economyread more
In its latest attempt to build market credibility, China on Monday launched the Science and Technology Innovation Board, or "STAR Market," on which 25 companies were listed.China Economyread more
When Cathy Hsu and Tony Hsieh wanted to build an English language app for Chinese children, they decided to follow Facebook and Google's lead.Start-upsread more
Stocks in Asia traded lower on Monday afternoon, as a Nasdaq-style technology board on the Shanghai Stock Exchange marked its debut.Asia Marketsread more
Instagram began tests that hide "like" counts on posts. That means influencers who market products on Instagram will have to rely on different metrics to show success.Technologyread more
Peter Neupert worked for Microsoft and Amazon-backed Drugstore.com, where he got to know Jeff Bezos. He now advises start-ups.Technologyread more
The firing of the tear gas was the latest confrontation between police and protesters who have taken to the streets for over a month to fight a proposed extradition bill and...China Politicsread more
Last week shows that oil prices are not the indicator for Middle East tensions they once were, and worries about global demand and growing U.S. production has changed that...Market Insiderread more
Facebook Vice President David Marcus is the face of the company's Libra digital currency, but the original driving force was a 26-year-old female corporate-development...Technologyread more
Allergan reported weaker-than-expected quarterly revenue after its Alzheimer's drug, Namenda IR, lost patent exclusivity and the company cut its full-year revenue forecast.
Shares of the pharmaceutical firm fell more than 3 percent in morning trade Monday, but recovered some of those losses and ended the day down about 2 percent at $248.31.
Allergan, known as Actavis until it bought Botox-maker Allergan last year and took on its name, cut its forecast for adjusted full-year net revenue to $14.65 billion to $14.90 billion, from its prior estimate of $17 billion.
The company's quarterly net revenue rose marginally, to $3.68 billion from $3.63 billion a year earlier, but this was far below the average Wall Street estimate of $4.08 billion.
Dublin-based Allergan's net loss attributable to ordinary shareholders increased to $571.3 million, or $1.44 per share, for the second quarter ended June 30, from $312.7 million, or 80 cents per share, a year earlier.
Excluding special items, the company earned $3.35 per share, beating the average analysts' estimate by 1 cent, according to Thomson Reuters I/B/E/S.
Pfizer dropped plans to buy Allergan for $160 billion in April after the U.S. government cracked down on so-called inversion deals, in which companies move their domicile to countries that have a lower tax rate.
The combination would have been the biggest deal ever in the pharmaceutical industry.
Allergan said last week it would sell its Anda distribution business for $500 million to Teva Pharmaceutical, a day after the Israeli drugmaker completed the $40.5 billion acquisition of Allergan's generic-drug portfolio.